A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VKA / vitamin K antagonists

[Related PubMed/MEDLINE]
Total Number of Papers: 1259
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VKA  (>> Co-occurring Abbreviation)
Long Form:   vitamin K antagonists
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients With Atrial Fibrillation. NOAC, UTI
2021 A Case of Duodenal Resection and Duodenojejunostomy for Multiple Small Bowel Infarction in Patient With Inherited Thrombophilia and Vitamin K Antagonist Induced Critical Hypocoagulation. LFV
2021 A New Method for the Measurement of International Normalized Ratio in Hemodialysis Patients with Heparin-Locked Tunneled Dialysis Catheters. INR, POCT, TDCs, UFH
2021 A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. DOACs, MPNs, VTE
2021 Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. VTE
2021 Anticoagulation in a Patient With Mechanical Prosthetic Valves and Calcific Uremic Arteriolopathy on Warfarin. CUA, ESRD, NSF
2021 Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of > 20000 patients. AF, GIB, ICB, IS, MB, NOACs, OR, OR, OR, TE
2021 Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. AF, DOAC
2021 Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial. AF, MAE, OAC
10  2021 Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. AF, ATT, ICH, NOAC, OAC
11  2021 Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. APS, AT, CI, DAPT, NOAC, RCTs, RR, RR, SAPT
12  2021 Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. NOACs, OAC
13  2021 Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance database. ADRs, EV, NS, PRR
14  2021 Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials. AF, CA, NOACs
15  2021 Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon? AF, NOACs, OAC
16  2021 Delayed intracranial hemorrhage after mild traumatic brain injury in patients on oral anticoagulants: is the juice worth the squeeze? CT, DOACs, ED, ICH, mTBI, PSM
17  2021 Direct oral anticoagulants and therapeutic adherence: do not let your guard down. DOAC
18  2021 Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older. DOAC, RCD, VTE
19  2021 Drug-drug interactions between vitamin K antagonists and statins: a systematic review. INR
20  2021 Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. AF, DOAC
21  2021 Efficacy and safety of direct oral anticoagulants for treatment of left ventricular thrombus; a systematic review. DOACs, GI, LVT
22  2021 Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. DOAC, ISTH, LMWH, OR, VTE
23  2021 Evaluation of anticoagulant therapy management in a teaching hospital in Tunisia: information and education for vitamin k antagonist newly treated patients need to be improved. ---
24  2021 Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists? DOAC, ED
25  2021 Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study. HMB, PBAC
26  2021 Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. ACS, MACCE, OAC, PCI, PRI, VASP
27  2021 Implementation and Evaluation of Virtual Anticoagulation Clinic Care to Provide Incessant Care During COVID-19 Times in an Indian Tertiary Care Teaching Hospital. ACC, PINRR, TTR, VAC
28  2021 Long-term oral anticoagulation for atrial fibrillation in low and middle income countries. AF, DOAC, INR, LMICs, OAC, RHD
29  2021 Management of left ventricular thrombus: a narrative review. AF, CMR, ECAs, EF, LV, LVEF, LVT, MI, STEMI
30  2021 Mechanical heart valve thrombosis during pregnancy under non-warfarin anticoagulation therapy: Two-case report and literature review. anti-Xa, LMWH, MHV, MVT
31  2021 Meta-analysis of direct oral anticoagulants compared with vitamin K antagonist for left ventricle thrombus. CI, DOAC, LV, OR
32  2021 Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. AF, CI, DOACs, OAC
33  2021 Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. NOAC, VSMC
34  2021 Oral anticoagulant therapy and outcome in patients with stroke. A retrospective nation-wide cohort study in Austria 2012-2017. NOAC
35  2021 Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists. DOACs, UGIB
36  2021 Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. DVT, GARFIELD, NPA-VTE, PA-VTE, PE, VTE
37  2021 Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation. DOAC, NVAF, OAC, OR, OR, VA
38  2021 Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis. CKD, DOACs, HR
39  2021 Risk of over-anticoagulation during acute kidney injury in patients treated with vitamin K antagonists. AKI, DOAC, INR
40  2021 Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report. DOACs
41  2021 Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist. DASS, HRQoL, PAPS, SF-36, TMA
42  2021 Therapeutic quality control in a regional thrombosis center: The effect of changing the target intensity of anticoagulation with vitamin K antagonists. NSM, TQC, TR, TTR
43  2021 Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. TTR
44  2021 Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018. aORs, DOAC, ICH
45  2021 Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis. INR
46  2021 [Anticoagulant and bone fragility: which implications for clinical practice?] NOACs
47  2021 [Anticoagulation after heart valve replacement]. NOAC
48  2020 A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. BMI, INR
49  2020 A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus? 4F-PCCs, DOAC
50  2020 Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter? ACT, AF, DOACs, UFH
51  2020 Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists. AIS, DOAC, OAC
52  2020 All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. AF, ARD, ARD, VHD
53  2020 American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. ASH, DVT, GRADE, INR, PE, VTE
54  2020 Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. AF
55  2020 Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists. DOAC, GIB
56  2020 Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. AF, NOACs
57  2020 Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. COVID-19, DOAC, ISTH, LMWH, UFH
58  2020 Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. AF, DOAC, ICH, VTE
59  2020 Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry. APD, DOAC, NVAF, OAT
60  2020 Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. ACS, CI, DAT, ICH, OAT, PCI, RCTs, ST, TAT, TIMI
61  2020 Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials. AF, CrI, NOACs, OR, PCI, TIMI
62  2020 Association of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis. AF, CI, NOAC, OACs, OR
63  2020 Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants. AF, NOAC, PCI
64  2020 Bedside Catheter Hematoma Evacuation in Vitamin K Antagonist-Related Intracerebral Hemorrhage: A Safe and Feasible Approach. ICH, MIS, MIS, PHE
65  2020 Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. ACS, CI, DAT, DOAC, MACE, OR, TAT
66  2020 Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. DOACs
67  2020 Bleeding and thrombotic risk in pregnant women with Fontan physiology. LMWH
68  2020 Blood Pressure and Anticoagulation Reversal Management during Off-Hours in Oral Anticoagulation-Associated Intracerebral Hemorrhage. BP, INR, mRS, NOAC, OAC-ICH, PSM
69  2020 Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. CUA
70  2020 Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry. AF, NOAC
71  2020 Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study. CES, HR, NOAC, NVAF
72  2020 Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. CRNM, MI, OD, PCI
73  2020 Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. ACT, DOAC
74  2020 Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis. CRNMB, DOACs, MB, MI, NMA, PE, R-DVT, RCTs, VTE
75  2020 Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. AF, CI, DOACs, HR
76  2020 Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. CVT, DOAC
77  2020 Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists. DOACs, GOS, tICH
78  2020 Correction of international normalised ratio in major bleeding related to vitamin K antagonists is associated with better survival: A UK study. ICH, INR, PCC, VK
79  2020 Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. NHS, NVAF
80  2020 Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing. NOAC, PSA, PST, SHI, TTR
81  2020 Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study. CI, DOACs
82  2020 Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. CAT, MB, VTE
83  2020 Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. AF, DCC, EDO, EDO, SE, TEE, TIA
84  2020 Direct oral anticoagulant use and outcomes in adult patients with Fontan circulation: A multicenter retrospective cohort study. DOACs
85  2020 Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. ATE/VTE, DOAC, MPN
86  2020 Direct oral anticoagulants and cardiac surgery: A descriptive study of preoperative management and postoperative outcomes. DOAC
87  2020 Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. DOAC, LV
88  2020 Direct oral anticoagulants for therapeutic anticoagulation in postoperative pulmonary embolism after meningioma resection. DOAC, KPS, LMWH, PE
89  2020 Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis. CI, DOAC, LMWH, MB, RR, VTE
90  2020 Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data. ACS, DOAC, LVT
91  2020 Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events. AF, CI, DOACs, PCI, RR, RR
92  2020 Direct-acting Anticoagulants in Chronic Coronary Syndromes. CCS, DAPT, DOACs, NVAF
93  2020 Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. AMS, INR, PSC, TTR
94  2020 Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis. DAT, DOAC, TAT
95  2020 Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study. AF, NOAC, PCI
96  2020 Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. ACS, AF, CCS, CI, HR, PCI, Pint
97  2020 Edoxaban versus warfarin in vitamin K antagonist experienced and naive patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. CI, enox-warf, ENSURE-AF, OR
98  2020 Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. INR, TTR
99  2020 Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. AF, hs-CRP, hs-IL-6, TAT
100  2020 Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. CAT, CRNMB, DOACs, LMWH